BioAtla, Inc. – NASDAQ:BCAB

Add to watchlist

$0.38

-0.25

-40.44%

Market open

Closed in about 6 hours

-64.56%

month

-64.56%

quarter

-79.94%

year

Market Cap	34.75M
Enterprise value	N/A

P/E	-1.11
EV/Sales	N/A
EV/EBITDA	0.44
Price/Sales	N/A
Price/Book	0.77
PEG ratio	-0.01
EPS	-2.49

Revenue	N/A
EBITDA	-124.31M
Income	-119.23M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

BioAtla, Inc. (NASDAQ:BCAB): Profit margin
Jun 2023	0	-35.75M
Sep 2023	0	-33.32M
Dec 2023	1.70M	-26.92M	-1578.25%
Mar 2024	0	-23.23M

BioAtla Financials Estimate

Q Y

BioAtla, Inc. (NASDAQ:BCAB): Analyst Estimates
Dec 2023	1.70M	-26.92M	-1578.25%
Mar 2024	0	-23.23M
Oct 2025	0	-18.59M
Dec 2025	0	-18.91M

Analysts Price target
Financials & Ratios estimates

BioAtla, Inc. (NASDAQ:BCAB): Earnings per share (EPS)
2023-11-07	-0.77	-0.7

BioAtla, Inc. (NASDAQ:BCAB): Debt to assets
Jun 2023	179637000	55.12M	30.68%
Sep 2023	151362000	56.65M	37.43%
Dec 2023	119658000	48.98M	40.94%
Mar 2024	89197000	39.48M	44.26%

BioAtla, Inc. (NASDAQ:BCAB): Cash Flow
Jun 2023	-24.09M	-15K	115
Sep 2023	-27.34M	-25K	-41
Dec 2023	-29.92M	-8K	119
Mar 2024	-30.82M	0	-13K

BioAtla alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

BioAtla, Inc. (NASDAQ:BCAB): Employee count
Aug 2023	66
Sep 2023	66
Oct 2023	66
Nov 2023	66
Dec 2023	66
Jan 2024	66
Feb 2024	66
Mar 2024	65
Apr 2024	65
May 2024	65
Jun 2024	65
Jul 2024	65

BioAtla
Hedge Funds Holdings Q3 2022

65.68% -3.76%

of BCAB is owned by hedge funds

63 -12

hedge funds hold BCAB stock

24.57M +1.03M

shares is hold by hedge funds

BCAB hedge funds holdings changes

BioAtla, Inc. (NASDAQ:BCAB): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	60800	0
Sep 2023	2000	0
Dec 2023	81495	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	26 Dec 2023	MCBRINN SYLVIA director director	Common Stock	4,000	$2.33	$9,320
Purchase	20 Dec 2023	SHORT JAY M PHD director, 10 perc..	Common Stock	50,000	$2.14	$106,900
Purchase	19 Dec 2023	VASQUEZ CHRISTIAN officer: See Remarks officer: See Remarks	Common Stock	7,495	$2.04	$15,260
Purchase	19 Dec 2023	STEINMAN LAWRENCE director director	Common Stock	20,000	$2.05	$41,040
Purchase	8 Sep 2023	MCBRINN SYLVIA director director	Common Stock	2,000	$2.54	$5,080
Purchase	29 Mar 2023	SHORT JAY M PHD director, 10 perc..	Common Stock	40,800	$2.47	$100,858
Purchase	28 Mar 2023	VASQUEZ CHRISTIAN officer: See Remarks officer: See Remarks	Common Stock	20,000	$2.4	$47,980
Purchase	19 Dec 2022	MCBRINN SYLVIA director director	Common Stock	3,700	$8.33	$30,814
Purchase	22 Nov 2022	MCBRINN SYLVIA director director	Common Stock	2,000	$8.27	$16,540
Purchase	13 Sep 2022	MCBRINN SYLVIA director director	Common Stock	1,000	$8.2	$8,200

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Comprehensive monoclonal antibody generation Filling date: 27 Apr 2020 Issue date: 26 Jul 2022	27 Apr 2020	26 Jul 2022
Grant	Grant Utility: Express humanization of antibodies Filling date: 22 Jan 2020 Issue date: 26 Jul 2022	22 Jan 2020	26 Jul 2022
Application	Application ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUCATES AND USES THEREOF Filling date: 23 Nov 2021 Issue date: 2 Jun 2022	23 Nov 2021	2 Jun 2022
Application	Application CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS Filling date: 11 Jan 2022 Issue date: 28 Apr 2022	11 Jan 2022	28 Apr 2022
Application	Application CONDITIONALLY ACTIVE POLYPEPTIDES AND METHODS OF GENERATING THEM Filling date: 13 Aug 2021 Issue date: 6 Jan 2022	13 Aug 2021	6 Jan 2022
Application	Application ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF Filling date: 3 Sep 2021 Issue date: 30 Dec 2021	3 Sep 2021	30 Dec 2021
Application	Application ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof Filling date: 25 Oct 2019 Issue date: 30 Dec 2021	25 Oct 2019	30 Dec 2021
Application	Application CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS Filling date: 30 Jul 2021 Issue date: 18 Nov 2021	30 Jul 2021	18 Nov 2021
Application	Application CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY Filling date: 20 Aug 2019 Issue date: 7 Oct 2021	20 Aug 2019	7 Oct 2021
Application	Application MULTI-SPECIFIC ANTIBODY CONSTRUCTS Filling date: 11 Jun 2019 Issue date: 19 Aug 2021	11 Jun 2019	19 Aug 2021

BioAtla
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 14 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 26 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 12 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 1 Aug 2023	Q2 2023 Earnings Call Transcript

BCAB earnings call transcripts

BioAtla
Executives

Insider	Age	Since	Compensation
Dr. Jay M. Short (1958) Co-Founder, Chief Executive Officer & Chairman	67		$1,060,000
Mr. Scott Andrew Smith (1962) Pres & Director	63		$824,510

BioAtla
Latest News

Friday, 20 December 2024
09:00	BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points	globenewswire.com
Monday, 16 December 2024
08:00	BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting	globenewswire.com
Tuesday, 10 December 2024
08:00	BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting	globenewswire.com
Saturday, 9 November 2024
08:53	BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 9 July 2024
10:47	3 Penny Stocks With 735% Average Upside, According to Wall Street	247wallst.com
Wednesday, 29 May 2024
08:00	BioAtla to Participate in the Jefferies Global Healthcare Conference	globenewswire.com
Thursday, 23 May 2024
17:05	BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	globenewswire.com
Tuesday, 14 May 2024
20:35	BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript	Seeking Alpha
Tuesday, 19 March 2024
08:00	BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	GlobeNewsWire
Sunday, 12 November 2023
05:38	BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 10 October 2023
07:30	BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023	GlobeNewsWire
Wednesday, 6 September 2023
08:00	BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference	GlobeNewsWire
Thursday, 3 August 2023
16:01	BioAtla to Participate in Upcoming Investor Conferences in August	GlobeNewsWire
Tuesday, 1 August 2023
23:18	BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 25 July 2023
08:00	BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023	GlobeNewsWire
Thursday, 11 May 2023
22:51	BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript	Seeking Alpha
Thursday, 4 May 2023
08:00	BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023	GlobeNewsWire
Thursday, 23 March 2023
22:33	BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript	Seeking Alpha
Wednesday, 18 January 2023
13:58	7 Cheap But Risky Biotech Stocks	Barrons
Tuesday, 15 November 2022
11:18	Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?	Zacks Investment Research
Sunday, 6 November 2022
11:47	BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript	Seeking Alpha
Friday, 4 November 2022
12:48	BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Thursday, 27 October 2022
08:00	BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022	GlobeNewsWire
Friday, 23 September 2022
16:12	BioAtla: Back From The Dead	Seeking Alpha
Tuesday, 23 August 2022
09:46	BioAtla: Promising Signal In NSCLC, But Concerns Remain	Seeking Alpha
Saturday, 13 August 2022
15:18	BioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 9 August 2022
21:04	BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
Tuesday, 2 August 2022
08:00	BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022	GlobeNewsWire
Wednesday, 1 June 2022
16:05	BioAtla to Participate in 2022 Jefferies Global Healthcare Conference	GlobeNewsWire
Saturday, 7 May 2022
15:06	BioAtla, Inc. (BCAB) CEO Jay Short on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha

Ideas & Opinions

Seeking Alpha 2 May 2024

BioAtla: A Buried ADC Concern Gets Some New Life In 2024
Seeking Alpha 23 Sep 2022

BioAtla: Back From The Dead
Seeking Alpha 23 Aug 2022

BioAtla: Promising Signal In NSCLC, But Concerns Remain
Seeking Alpha 10 Oct 2021

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products

Frequently Asked Questions (FAQ)

What's the price of BioAtla stock today?

One share of BioAtla stock can currently be purchased for approximately $0.38.
When is BioAtla's next earnings date?

Unfortunately, BioAtla's (BCAB) next earnings date is currently unknown.
Does BioAtla pay dividends?

No, BioAtla does not pay dividends.
How much money does BioAtla make?

BioAtla has a market capitalization of 34.75M. BioAtla made a loss 123.46M US dollars in net income (profit) last year or -$0.7 on an earnings per share basis.
What is BioAtla's stock symbol?

BioAtla, Inc. is traded on the NASDAQ under the ticker symbol "BCAB".
What is BioAtla's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of BioAtla?

Shares of BioAtla can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are BioAtla's key executives?
BioAtla's management team includes the following people:
- Dr. Jay M. Short Co-Founder, Chief Executive Officer & Chairman(age: 67, pay: $1,060,000)
- Mr. Scott Andrew Smith Pres & Director(age: 63, pay: $824,510)
Is BioAtla founder-led company?

Yes, BioAtla is a company led by its founder Dr. Jay M. Short.
How many employees does BioAtla have?

As Jul 2024, BioAtla employs 65 workers.
When BioAtla went public?

BioAtla, Inc. is publicly traded company for more then 4 years since IPO on 16 Dec 2020.
What is BioAtla's official website?

The official website for BioAtla is bioatla.com.
Where are BioAtla's headquarters?

BioAtla is headquartered at 11085 Torreyana Road, San Diego, CA.
How can i contact BioAtla?

BioAtla's mailing address is 11085 Torreyana Road, San Diego, CA and company can be reached via phone at 858 558 0708.

BioAtla, Inc.

bioatla.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

858 558 0708

11085 Torreyana Road
San Diego, CA 92121

CIK: 0001826892
ISIN: US09077B1044
CUSIP: 09077B104